Asset Details
Do you wish to reserve the book?
Therapy of early breast cancer: current status and perspectives
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Therapy of early breast cancer: current status and perspectives
Do you wish to request the book?
Therapy of early breast cancer: current status and perspectives
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Therapy of early breast cancer: current status and perspectives
2025
Overview
Medical advancements in breast cancer are truly remarkable. Especially in recent years, numerous new therapeutics have been approved and surgical strategies have been de-escalated for specific patient groups. In the therapeutic setting, CDK4/6 inhibitors as oral maintenance therapy in early breast cancer and immune checkpoint inhibitors (Pembrolizumab) for triple-negative breast cancer (BC) are noteworthy. In the surgical field, prospective randomized controlled trials have currently explored the possibility to deescalate axillary surgery by omitting sentinel lymph node excision (INSEMA, SOUND). As a result, there have been significant improvements in prognosis and a reduction in surgical morbidity for patients. Many exciting trials are underway, and it remains to be seen whether antibody–drug conjugates beyond trastuzumab emtansine, will find their way into the treatment lines for early-stage BC. Furthermore, the integration of artificial intelligence in both diagnostics and treatment recommendation evaluation is a promising area with great potential.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
Antibodies, Monoclonal, Humanized - therapeutic use
/ Biopsy
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - pathology
/ Cyclin-Dependent Kinase 4 - antagonists & inhibitors
/ Female
/ Humans
/ Immune Checkpoint Inhibitors - therapeutic use
/ Medicine
/ Obstetrics/Perinatology/Midwifery
/ Patients
/ Randomized Controlled Trials as Topic
/ Review
/ Triple Negative Breast Neoplasms - drug therapy
/ Triple Negative Breast Neoplasms - pathology
